Tappet

← Back to Tappet
Conshohocken feed of tappet.org
Education · Nov 19, 2026

Bioadvance - ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN

TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix License supports lifecycle management of the PMN310 franchise, with options to extend TXP1 to ProMIS’s Parkinson’s and ALS programs Cambridge, Massachusetts, Nov. 17, 2026 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN),...

https://bioadvance.com/promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline/?utm_source=rss&utm_medium=rss&utm_campaign=promis-neurosciences-licenses-next-generation-txp1-brain-selective-shuttling-technology-from-ossianix-to-expand-pmn310-franchise-and-pipeline

Join the conversation on Tappet